COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE TYPE 2 DIABETIC PATIENTS WITH MICROALBUMINURIA IN TAIWAN

Yang WC1, Anнемans L2, Ng YY1, Hwang SJ1

1Taipei Veterans General Hospital, Taipei, Taiwan; 2Ghent University, Meise, Belgium; 3Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

OBJECTIVES: To project the cumulative incidence of end-stage renal disease (ESRD), life expectancy and costs in Taiwan of treating patients with diabetes, hypertension, and microalbuminuria (DHM) with either standard hypertension treatment (i.e. start treatment in subjects with microalbuminuria) or (ii) standard hypertension treatment plus irbesartan 300mg daily. METHODS: A peer-reviewed, published Markov model that simulated progression from microalbuminuria to nephropathy, doubling of serum creatinine, ESRD, and all-cause mortality in patients with DHM was adapted to Taiwan. Three strategies were compared: (i) early use of irbesartan (i.e. start treatment in subjects with microalbuminuria) versus (ii) late use of irbesartan (i.e. as from overt nephropathy), or (iii) standard hypertension care (with comparable blood pressure control). Cumulative incidence of ESRD, costs and life expectancy were projected for a hypothetical cohort of 1000 subjects. Treatment-specific progression and mortality probabilities were derived from published trials: IRMA-2 (in microalbuminuria) and IDNT (in overt nephropathy). Medical management and cost data per state were obtained from published local sources. A flexible time horizon up to 25-years and third party payer perspective were used. Future costs and LE were discounted at 3% yearly.

RESULTS: When compared to standard blood pressure control, early irbesartan was projected to reduce the cumulative incidence of ESRD from (mean ± standard deviation) 22% to 8%, save TN $248,302 (US $7303), and add 0.702 life years per treated patient. Late irbesartan was dominant to control but dominated by early irbesartan. The superiority of early use of irbesartan over standard care was robust for most variables, except for the cost of dialysis and the time horizon. Break-even occurred after 12 years.

CONCLUSIONS: Treating DHM patients with early irbesartan was projected to reduce the incidence of ESRD, extend life and reduce costs. Treating patients at a later stage is still beneficial, however to a lower extent. Applying flexible time horizons shows additional relevant information to decision makers.

TIME TO LDL-CHOLESTEROL GOAL ATTAINMENT IN SPAIN

Olivares Q1, Mabe I2, Noceca G3, Alemao E4, Caloto T5, Fosbrook L6, Ahumada C7, Yin D8

1CS Pedro la Mata, Albacete, Spain; 2CS Bidezabal, Vizcaya, Spain; 3Merc, Sharp & Dohme de España, Madrid, Spain; 4Merc, & Co, Whitehouse Station, NJ, USA; 5 Shering Plough, Madrid, Spain

Majority of patients treated for hyperlipidemia with available cholesterol lowering drugs (LLD) do not achieve recommended LDL-C goal in Spain. OBJECTIVES: To assess LDL-C reduction and goal attainment over time and determine time period when patients are most likely to attain goal after initiation of LLD in Spain. METHODS: Retrospective cohort study conducted at 23 primary care centres and 16 outpatient lipid centres. Eligible patients were adults (≥18 years) with CHD/CHD equivalent or 2+ major risk factors (2+ RF) prior to first prescription of LLD between January 1998–April 1999, and ≥36 months of follow-up data after. LDL-C goals were based on NCEP III guidelines (100mg/dl for CHD/CHD equivalent patients, 130mg/dl for 2+ RF group). Goal attainment analyses were based on proportion of patients at goal from those with a valid LDL-C measure at 3 month time intervals from therapy start, and on increase or decrease in that proportion for subsequent periods.

RESULTS: A total of 619 patients (46% CHD/CHD equivalent and 54% nonCHD with 2+ RFs) were included in the study. Mean age was 60 years (SD 10.22), 48% were female. Statins were initial LLD in 90% patients. Only 20% CHD and 29% 2+ RF patients were at goal at study end. Proportion of patients at goal increased to 23% after 3 months of therapy start and remained stable afterwards around 25%. Increase in proportion of patients at goal was only positive (+23%) for the first 3 months (p < 0.05) and then remained around 0% increase till study end.

CONCLUSIONS: Percentage of patients at goal only increased during first three month period after start of lipid lowering therapy, remaining flat thereafter. More aggressive lipid lowering therapy should be started for those not at goal after first 3 months from LLD start, to enable more patients to get to LDL-C goal.